1-(2-chloro-6-propoxypyridin-4-yl)-3-((7-isopropyl-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)methyl)urea | 1285387-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1-(2-chloro-6-propoxypyridin-4-yl)-3-((7-isopropyl-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-5-yl)methyl)urea
• 英文别名: 1-(2-Chloro-6-propoxypyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea
• CAS: 1285387-27-0
• 化学式: C₂₁H₂₇ClN₆O₂
• 分子量: 430.937
• InChiKey: UJYZFHIZYGZTEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS<br/>[FR] COMPOSÉS PYRIDINES À NOYAUX CONDENSÉS COMME MODULATEURS SÉLECTIFS D'UN SOUS-TYPE DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE-2 (S1P2)
  申请人：ALLERGAN INC

  公开号：WO2011041287A1

  公开（公告）日：2011-04-07

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  该发明提供了由公式I表示的化合物，其中每个化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，这些化合物选自由A、B、C、D、X、Y、Z和R3定义的组成的组中。所述化合物适用于治疗从眼部疾病；全身血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或症状；纤维化；疼痛和伤口中选择的哺乳动物的疾病或症状。
• Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors
  申请人：Fang Wenkiu K.

  公开号：US20120208840A1

  公开（公告）日：2012-08-16

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R 3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  该发明提供了由公式I表示的化合物，每个化合物都可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，其中这些化合物选自由A、B、C、D、X、Y、Z和R3定义的组中。这些化合物可用于治疗哺乳动物的疾病或病况，所述哺乳动物的疾病或病况选自眼部疾病；系统性血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或病况；纤维化；疼痛和伤口。
• Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition
  申请人：DALHOUSIE UNIVERSITY

  公开号：US10058543B2

  公开（公告）日：2018-08-28

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.

  本研究提供了通过施用治疗有效量的2型磷酸肾上腺素受体（S1PR2）抑制剂来治疗家族性渗出性玻璃体视网膜病变（FEVR）和早产儿视网膜病变（ROP）的方法和组合物。
• S1PR2 antagonists and uses therefor
  申请人：DALHOUSIE UNIVERSITY

  公开号：US10487082B2

  公开（公告）日：2019-11-26

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-3-((2,6-dichloropyridin-4-yl)amino)-3-(((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)amino)acrylonitrile and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

  本文提供了通过施用治疗有效量的鞘氨醇-1-磷酸受体 2 型（S1PR2）拮抗剂治疗家族性渗出性玻璃体视网膜病变（FEVR）的方法和组合物。本文还提供了(Z)-3-((2,6-二氯吡啶-4-基)氨基)-3-(((4-异丙基-1,3-二甲基-1H-吡唑并[3,4-b]吡啶-6-基)甲基)氨基)丙烯腈及其类似物，以及它们在治疗视网膜病变和以血管生成不足为特征的疾病中的用途。
• TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION
  申请人：Dalhousie University

  公开号：EP3148550A1

  公开（公告）日：2017-04-05